LY2484595 + rosuvastatin

**LY2484595 + rosuvastatin** is a combination of two distinct drugs. LY2484595 is known as **evacetrapib**, a cholesteryl ester transfer protein (CETP) inhibitor developed to increase high-density lipoprotein cholesterol (HDL-C) and decrease low-density lipoprotein cholesterol (LDL-C) in patients with lipid disorders. **Rosuvastatin** is a widely used statin that inhibits HMG-CoA reductase to lower LDL-C and cardiovascular risk. The combination was tested in clinical development to evaluate additive efficacy and safety in hypercholesterolemia or low HDL-C, specifically targeting atherosclerotic risk. The rationale behind the combination is to target heart disease through two complementary mechanisms: enhanced HDL-C raising/LCL-C lowering by CETP inhibition and potent LDL-C reduction by statins[1][2][3][4].

Other names

evacetrapib + rosuvastatin